Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
5-Azacytidine (HB1374)
Description:DNA methyltransferase inhibitor. Improves stem cell reprogramming efficiency and induces differentiation of MSCs into cardiomyocytes.
Purity:>98%
-
SP600125 (HB2234)
Description:Selective, ATP-competitive JNK inhibitor. Prevents BMP9-induced osteogenic MSC differentiation. Maintains stem cells in naive pluripotent state.
Purity:>98%
-
Zebularine (HB1378)
Description:DNA methyltransferase inhibitor. Induces cardiomyocyte differentiation in MSCs.
Purity:>99%
